CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:CSF1R-CAR T cells induce CSF1R signaling and can promote target cell proliferation.
CSF1R-CAR T cells induce CSF1R signaling and can promote target cell proliferation.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
嵌合抗原受体(CAR)T细胞在治疗复发/难治性血液肿瘤方面已展现出前所未有的成功。既往关于CAR-T 细胞与其靶细胞之间相互作用及应答机制的研究,大多忽略了肿瘤对CAR连接的应答。
我们比较了两种CAR的信号传导:一种是由集落刺激因子1(CSF1)构建、靶向靶细胞上CSF1受体(CSF1R)的第二代配体型CAR,另一种是靶向B细胞抗原CD19的常规单链可变片段型CAR。通过SILAC共培养联合磷酸化酪氨酸富集及LC-MS/MS分析,我们发现表达CSF1R的THP-1细胞与CSF1R-CAR-T 细胞连接后,THP-1细胞中触发了CSF1R样信号传导。相比之下,CD19-CAR-T 细胞与靶细胞Raji细胞连接后,未观察到靶细胞的信号应答。利用靶向酪氨酸激酶Lck、肌动蛋白聚合及CSF1R的小分子抑制剂,我们发现CAR诱导的THP-1细胞CSF1R信号完全依赖于CSF1R自身的激酶活性,而与T细胞活化无关。与此一致的是,CSF1R-CAR-T 细胞在低效靶比时促进THP-1细胞增殖,而在高效靶比时则抑制THP-1细胞增殖。
我们的数据为CAR在靶细胞中诱导信号传导提供了证据,这是CAR的一种非预期效应,可能对选择CAR抗原以获得最佳临床疗效具有参考意义。
Chimeric antigen receptor (CAR) T cells have demonstrated unprecedented success in treating relapsed or refractory blood cancers. Previous studies of the mechanisms underlying the interactions and responses of CAR T cells and their targets have largely ignored the responses of tumors to CAR ligation.
We compared the signaling of a second-generation, ligand-based CAR built from colony-stimulating factor 1 (CSF1) to target the CSF1 receptor (CSF1R) on target cells with a conventional, single-chain variable fragment-based CAR against the B cell antigen CD19. Using SILAC coculture with phosphotyrosine enrichment and LC-MS/MS analysis, we showed that ligation of CSF1R-expressing THP-1 cells with CSF1R-CAR T cells stimulated CSF1R-like signaling in the THP-1 cells.
In contrast, no target cell signaling response was observed after the ligation of CD19-CAR T cells with target Raji cells. Using small-molecule inhibitors of the tyrosine kinase Lck, actin polymerization, and CSF1R, we found that CAR-induced CSF1R signaling in THP-1 cells depended exclusively on the kinase activity of CSF1R with no participation from T cell activation. Consistently, CSF1R-CAR T cells promoted THP-1 cell proliferation at low effector-to-target ratios but prevented THP-1 cell proliferation at high effector-to-target ratios.
Our data provide evidence for CAR-induced signaling in target cells, an unintended consequence of CARs that may have implications for the choice of CAR antigen for optimal clinical efficacy.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。